Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML By Ogkologos - September 14, 2026 83 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PARADIGM study Source RELATED ARTICLESMORE FROM AUTHOR Non-pharmacological interventions – are they important to patients with cancer? Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer MOST POPULAR FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML in Paediatric Patients June 23, 2020 Feasibility and Preliminary Efficacy Results of the Beat AML Study October 28, 2020 Determination of the Incidence of Driver Mutations in Patients with NSCLC... March 24, 2021 ΚΑΡΚΙΝΟΣ ΠΑΧΕΩΣ ΕΝΤΕΡΟΥ February 10, 2019 Load more HOT NEWS Latest episode of our podcast for researchers Cancer-Free Bell Broken by Excited Patient Who Just Got Done Battling... ESMO Asia Congress 2023, 1-3 December 2023, Singapore Cancer in My Community: Obstacles to Caring for People With Cancer...
